Skip to content

A comparative study of the bowel cleansing between 1L-PEG and 2L-PEG

Bowel Cleansing Efficacy and Safety with 1L-Polyethylene Glycol with Ascorbic acid versus 2L-Polyethylene Glycol with ascorbic acid as Split Doses Preparation: A prospective, single-center, noninferiority, randomized controlled trial.

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
CRIS
Registry ID
KCT0006313
Enrollment
250
Registered
2021-07-02
Start date
2021-07-08
Completion date
Unknown
Last updated
2022-01-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Drug : In this study, there are two kinds of cleaning agents, coolprep and cleanviewl. Bowel cleansing solutions differ in dosage and composition. The Coolprep is 2L-PEG based solutions but, cleanview

Sponsors

Korea University Anam Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: (1)Age: Adults aged 19 to 85 years old. (2)A prospective colonoscopy person who is referred to the endoscopy center.

Exclusion criteria

Exclusion criteria: (1) Colon obstruction (2) Active colonic bleeding (3) GFR < 30 (4) Active Inflammatory bowel disease, Pregnancy (5) Bowel resection and abdominal surgery (6) Person who refuse to provide consent (7) Previous history of allergy to bowel cleansing solutions, bean and eggs (8) Systolic blood pressure less than 80mmHg or Oxygen saturation less than 90%, unstable hemodynamics

Design outcomes

Primary

MeasureTime frame
Overall bowel successful cleansing rate;Right colon successful cleansing rate

Secondary

MeasureTime frame
Adenoma detection rate and Polyp detection rate;Acceptance and tolerability;Electrolyte imbalance;Bowel cleansing efficacy according to constipation and stool form;Adverse event;Cecal intubation and withdrawal time

Countries

Korea, Republic of

Contacts

Public ContactHan Jo Jeon

Korea University Anam Hospital

roadstar82@naver.com+82-2-920-6555

Outcome results

None listed

Source: CRIS (via WHO ICTRP) · Data processed: Feb 4, 2026